These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

309 related articles for article (PubMed ID: 21468783)

  • 1. Evaluation of HER2 protein expression in gastric carcinomas: comparative analysis of 1,414 cases of whole-tissue sections and 595 cases of tissue microarrays.
    Kim KC; Koh YW; Chang HM; Kim TH; Yook JH; Kim BS; Jang SJ; Park YS
    Ann Surg Oncol; 2011 Oct; 18(10):2833-40. PubMed ID: 21468783
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A large cohort of consecutive patients confirmed frequent HER2 positivity in gastric carcinomas with advanced stages.
    Cho J; Jeong J; Sung J; Sung CO; Kim KM; Park CK; Choi MG; Sohn TS; Bae JM; Kim S
    Ann Surg Oncol; 2013 Dec; 20 Suppl 3():S477-84. PubMed ID: 23274580
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Overexpression of GRP78 and GRP94 are markers for aggressive behavior and poor prognosis in gastric carcinomas.
    Zheng HC; Takahashi H; Li XH; Hara T; Masuda S; Guan YF; Takano Y
    Hum Pathol; 2008 Jul; 39(7):1042-9. PubMed ID: 18482745
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic implications of altered human epidermal growth factor receptors (HERs) in gastric carcinomas: HER2 and HER3 are predictors of poor outcome.
    Begnami MD; Fukuda E; Fregnani JH; Nonogaki S; Montagnini AL; da Costa WL; Soares FA
    J Clin Oncol; 2011 Aug; 29(22):3030-6. PubMed ID: 21709195
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Approaching heterogeneity of human epidermal growth factor receptor 2 in surgical specimens of gastric cancer.
    Asioli S; Maletta F; Verdun di Cantogno L; Satolli MA; Schena M; Pecchioni C; Botta C; Chiusa L; Molinaro L; Conti L; Viale G; Ingravallo G; Maiorano E; Sapino A
    Hum Pathol; 2012 Nov; 43(11):2070-9. PubMed ID: 22658277
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comprehensive analysis of HER2 expression and gene amplification in gastric cancers using immunohistochemistry and in situ hybridization: which scoring system should we use?
    Park YS; Hwang HS; Park HJ; Ryu MH; Chang HM; Yook JH; Kim BS; Jang SJ; Kang YK
    Hum Pathol; 2012 Mar; 43(3):413-22. PubMed ID: 21855114
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Expression of HER-2 and leptin in gastric cancer and their clinical significance].
    Geng YT; Qiu JR; Wang R; Su YT; Shu YQ; Yin YM
    Zhonghua Zhong Liu Za Zhi; 2011 Oct; 33(10):764-9. PubMed ID: 22335909
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic significance of perineural invasion in patients with gastric cancer who underwent curative resection.
    Bilici A; Seker M; Ustaalioglu BB; Kefeli U; Yildirim E; Yavuzer D; Aydin FM; Salepci T; Oncel M; Gumus M
    Ann Surg Oncol; 2010 Aug; 17(8):2037-44. PubMed ID: 20333555
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic value of NDRG1 and SPARC protein expression in breast cancer patients.
    Nagai MA; Gerhard R; Fregnani JH; Nonogaki S; Rierger RB; Netto MM; Soares FA
    Breast Cancer Res Treat; 2011 Feb; 126(1):1-14. PubMed ID: 20369286
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cytoplasmic CD24 expression is a novel prognostic factor in diffuse-type gastric adenocarcinoma.
    Chou YY; Jeng YM; Lee TT; Hu FC; Kao HL; Lin WC; Lai PL; Hu RH; Yuan RH
    Ann Surg Oncol; 2007 Oct; 14(10):2748-58. PubMed ID: 17680316
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Decreased expression of RASSF6 is a novel independent prognostic marker of a worse outcome in gastric cancer patients after curative surgery.
    Wen Y; Wang Q; Zhou C; Yan D; Qiu G; Yang C; Tang H; Peng Z
    Ann Surg Oncol; 2011 Dec; 18(13):3858-67. PubMed ID: 21442347
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Arp2/3 overexpression contributed to pathogenesis, growth and invasion of gastric carcinoma.
    Zheng HC; Zheng YS; Li XH; Takahashi H; Hara T; Masuda S; Yang XH; Guan YF; Takano Y
    Anticancer Res; 2008; 28(4B):2225-32. PubMed ID: 18751399
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of four immunohistochemical tests and FISH for measuring HER2 expression in gastric carcinomas.
    Cho EY; Srivastava A; Park K; Kim J; Lee MH; Do I; Lee J; Kim KM; Sohn TS; Kang WK; Kim S
    Pathology; 2012 Apr; 44(3):216-20. PubMed ID: 22437741
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prediction of sites of recurrence in gastric carcinoma using immunohistochemical parameters.
    Saito H; Osaki T; Murakami D; Sakamoto T; Kanaji S; Ohro S; Tatebe S; Tsujitani S; Ikeguchi M
    J Surg Oncol; 2007 Feb; 95(2):123-8. PubMed ID: 17262742
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expression of HER2 and its association with AP-2 in breast cancer.
    Pellikainen J; Naukkarinen A; Ropponen K; Rummukainen J; Kataja V; Kellokoski J; Eskelinen M; Kosma VM
    Eur J Cancer; 2004 Jul; 40(10):1485-95. PubMed ID: 15196531
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinicopathologic characteristics of patients with stage III/IV (M(0)) advanced gastric cancer, according to HER2 status assessed by immunohistochemistry and fluorescence in situ hybridization.
    Im SA; Kim JW; Kim JS; Kim MA; Jordan B; Pickl M; Han SW; Oh DY; Lee HJ; Kim TY; Kim WH; Yang HK; Bang YJ
    Diagn Mol Pathol; 2011 Jun; 20(2):94-100. PubMed ID: 21532492
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical implication of CXCL12 expression in gastric cancer.
    Ishigami S; Natsugoe S; Okumura H; Matsumoto M; Nakajo A; Uenosono Y; Arigami T; Uchikado Y; Setoyama T; Arima H; Hokita S; Aikou T
    Ann Surg Oncol; 2007 Nov; 14(11):3154-8. PubMed ID: 17653799
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Protein expression of HER2, 3, 4 in gastric cancer: correlation with clinical features and survival.
    He XX; Ding L; Lin Y; Shu M; Wen JM; Xue L
    J Clin Pathol; 2015 May; 68(5):374-80. PubMed ID: 25731189
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High expression of HER3 is associated with a decreased survival in gastric cancer.
    Hayashi M; Inokuchi M; Takagi Y; Yamada H; Kojima K; Kumagai J; Kawano T; Sugihara K
    Clin Cancer Res; 2008 Dec; 14(23):7843-9. PubMed ID: 19047113
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of expression of human epidermal growth factor receptors EGFR and ERBB2 on survival in stage II/III gastric cancer.
    Terashima M; Kitada K; Ochiai A; Ichikawa W; Kurahashi I; Sakuramoto S; Katai H; Sano T; Imamura H; Sasako M;
    Clin Cancer Res; 2012 Nov; 18(21):5992-6000. PubMed ID: 22977193
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.